Shots:

• The PR status is based on P-II DREAMM-2 study assessing two doses of Belantamab Mafodotin (GSK2857916) in patients with r/r MM who are refractory to a proteasome inhibitor and an immunomodulatory agent with failed prior treatment with an anti-CD38 antibody
• In 2017- the US FDA has granted the BT designation to therapy. Following its approval. It will be the first anti-BCMA therapy available to patients with MM
• Belantamab mafodotin is an investigational anti-BMCA mAb conjugated to the cytotoxic agent auristatin F via a non-cleavable linker and is developed utilizing POTELLIGENT technology licensed from BioWa

Click here ­to­ read full press release/ article 

Ref: GSK | Image: GSK